利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.022 秒)

    Mesoscale MEMS switch apparatus and method
    1.
    发明授权
    Mesoscale MEMS switch apparatus and method 失效
    中尺度MEMS开关设备及方法

    公开(公告)号：US06800820B1

    公开(公告)日：2004-10-05

    申请号：US10411490

    申请日：2003-04-10

    申请人： Junhua Liu ,  William Olson

    发明人： Junhua Liu ,  William Olson

    IPC分类号： H01H5700

    CPC分类号： H01H59/0009 ,  H01H2001/0073

    摘要： A plurality of mesoscale MEMS switches each share a common control voltage potential electrode (such as ground). So configured, a large number of switches can be provided without incurring a significant increase in required actuation voltage. Such switches can be inter-coupled in a variety of ways. In addition, in one embodiment, stacked switches can be provided. If desired, such stacked switches can share a common movable conductive switch element.

    摘要翻译： 多个中尺度MEMS开关各自共享公共控制电压电位（例如接地）。 如此配置，可以提供大量的开关，而不会导致所需的致动电压的显着增加。 这种开关可以以各种方式互连。 此外，在一个实施例中，可以提供堆叠的开关。 如果需要，这种堆叠式开关可以共用公共的可移动导电开关元件。

    CD4-IgG2 formulations
    3.
    发明申请
    CD4-IgG2 formulations 审中-公开
    CD4-IgG2制剂

    公开(公告)号：US20050142139A1

    公开(公告)日：2005-06-30

    申请号：US10804802

    申请日：2004-03-19

    申请人： Norbert Schulke ,  William Olson ,  Cherie Parkhurst-Lang ,  Indu Isaacs

    发明人： Norbert Schulke ,  William Olson ,  Cherie Parkhurst-Lang ,  Indu Isaacs

    IPC分类号： A61K20060101 ,  A61K31/4172 ,  A61K39/00 ,  A61K39/395 ,  C07K1/00 ,  C07K16/00 ,  C12N5/20

    CPC分类号： C07K14/70514 ,  A61K47/6425 ,  A61K47/6835 ,  C07K2319/00 ,  C07K2319/30

    摘要： This invention provides formulations of the anti-HIV therapeutic, CD4-IgG2, that contain higher concentrations of the therapeutic than were previously prepared, are stable, compatible with lyophilization, and safe to administer. These formulations are suitable for intravenous, subcutaneous and intramuscular delivery, the latter two routes being potentially useful for facilitating self-administration by HIV-infected individuals. This invention is also directed to methods of making the CD4-IgG2 formulations described in the disclosure, and methods of using the formulations to inhibit or prevent infect CD4+ cells from becoming infected with HIV, and to treat subjects having CD4+ cells infected with HIV.

    摘要翻译： 本发明提供了抗HIV治疗剂CD4-IgG2的制剂，其含有比先前制备的更高浓度的治疗剂，其是稳定的，与冻干相容并且安全施用。 这些制剂适用于静脉内，皮下和肌内递送，后两种途径可能有助于促进HIV感染个体的自我施用。 本发明还涉及制备本公开中描述的CD4-IgG2制剂的方法，以及使用制剂抑制或预防感染CD4 +细胞感染HIV的方法，以及治疗感染HIV的CD4 +细胞的受试者的方法。

    Method for obtaining blood pressure data from optical sensor
    4.
    发明授权
    Method for obtaining blood pressure data from optical sensor 有权
    从光学传感器获得血压数据的方法

    公开(公告)号：US06475153B1

    公开(公告)日：2002-11-05

    申请号：US09568781

    申请日：2000-05-10

    申请人： Mohammad Khair ,  Salvador Lopez ,  Richard Ng ,  Sanjar Ghaem ,  William Olson

    发明人： Mohammad Khair ,  Salvador Lopez ,  Richard Ng ,  Sanjar Ghaem ,  William Olson

    IPC分类号： A61B502

    CPC分类号： A61B5/6843 ,  A61B5/02007 ,  A61B5/021 ,  A61B5/02416 ,  A61B5/0261 ,  A61B5/681 ,  A61B5/7285 ,  A61B2562/0233 ,  A61B2562/046

    摘要： An optical sensor generates blood pressure data by obtaining two dimensional images of the surface of the patient's body, such as in the vicinity of the radial artery in the wrist area. Blood flow in the patient causes light to be reflected off a flexible reflective surface applied against the patient with a hold down pressure, and the scattering of light is sensed with a two-dimensional array of photo-detectors. The output of the photo-detectors during systolic and diastolic events is calibrated against known blood pressure measurements taken with a conventional air-cuff sphygmomanometer. Linear calibration relationships between output signal and blood pressure are obtained during calibration for some set of the photo-detectors. When blood pressure data is obtained from the patient, the linear calibration relationship between output signals and blood pressure is applied to the output signals from the set of photo-detectors, resulting in blood pressure data. The method provides for compensation for changes in hold down pressure and translation or rotation of the optical sensor relative to the patient. A preferred optical sensor arrangement for use in performing the method is also described.

    摘要翻译： 光学传感器通过获得患者身体的表面的二维图像，例如在手腕区域中的桡动脉附近来产生血压数据。 患者的血液流动导致光被从按压压力施加到患者上的柔性反射表面反射出来，并且用二维光电检测器阵列感测光的散射。 收缩期和舒张期事件期间光电探测器的输出是用常规气袖血压计测量的已知血压进行校准。 在一些光电检测器的校准期间，可以获得输出信号与血压之间的线性校准关系。 当从患者获得血压数据时，输出信号和血压之间的线性校准关系被施加到来自该组光电检测器的输出信号，从而产生血压数据。 该方法提供补偿压力压力和光学传感器相对于患者的平移或旋转的变化。 还描述了用于执行该方法的优选光学传感器装置。

    UNTUCKING RESISTANT GARMENT
    6.
    发明申请
    UNTUCKING RESISTANT GARMENT 有权

    公开(公告)号：US20230085435A1

    公开(公告)日：2023-03-16

    申请号：US17476581

    申请日：2021-09-16

    申请人： William Olson ,  Travis Buysse

    发明人： William Olson ,  Travis Buysse

    IPC分类号： A41B1/08 ,  A41D27/08

    摘要： An untucking resistant garment resists becoming untucked while being worn. The garment includes a garment body and an inner band of tacky material coupled to an inside surface of the garment body positioned proximate to a bottom opening of the garment body. An outer band of the tacky material is coupled to an outside surface of the garment body positioned proximate to the bottom opening.

    Compositions comprising anti-CCR5 antibody
    7.
    发明申请
    Compositions comprising anti-CCR5 antibody 审中-公开
    包含抗CCR5抗体的组合物

    公开(公告)号：US20070274986A1

    公开(公告)日：2007-11-29

    申请号：US11804746

    申请日：2007-05-17

    申请人： William Olson ,  Paul Maddon

    发明人： William Olson ,  Paul Maddon

    IPC分类号： A61K39/395 ,  C07K16/44

    CPC分类号： A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2866 ,  C07K2317/76 ,  A61K2300/00

    摘要： This invention provides a composition which comprises a monoclonal antibody or a fragment of such antibody, wherein the monoclonal antibody or fragment of such antibody binds to the same epitope as antibody PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) and a carrier. This invention also provides a method of treating a subject infected with HIV-1 which comprises administering to the subject an effective dose of the composition of the invention.

    摘要翻译： 本发明提供了包含单克隆抗体或该抗体片段的组合物，其中单克隆抗体或该抗体的片段与由指定为PA14（ATCC登录号HB-12610）的杂交瘤细胞系产生的抗体PA14相同的表位结合 ）和运营商。 本发明还提供了一种治疗感染HIV-1的受试者的方法，其包括向受试者施用有效剂量的本发明组合物。

    Anti-CCR5 antibody
    8.
    发明申请
    Anti-CCR5 antibody 有权
    抗CCR5抗体

    公开(公告)号：US20070031408A1

    公开(公告)日：2007-02-08

    申请号：US11581945

    申请日：2006-10-16

    申请人： William Olson ,  Paul Maddon ,  Naoya Tsurushita ,  Paul Hinton ,  Maximillano Vasquez

    发明人： William Olson ,  Paul Maddon ,  Naoya Tsurushita ,  Paul Hinton ,  Maximillano Vasquez

    IPC分类号： A61K39/395 ,  C07K16/28 ,  C07K16/10

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

    摘要： The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.

    摘要翻译： 本发明涉及抗CCR5抗体，其包含（i）两条轻链，每条轻链包含命名为pVK：HuPRO14O-VK（ATCC保藏号PTA-4097）的质粒的表达产物，和（ii）两条重链 每个重链包含称为pVgl：HuPRO140HG2-VH（ATCC保藏号PTA-4098）或质粒命名为pVgl：HuPRO140（mutB + D + I）-VH（ATCC保藏号PTA-4099）的质粒的表达产物 ）或其与人细胞表面上的CCR5结合的片段。

    L-SIGN polymorphisms and methods involving use of same
    9.
    发明申请
    L-SIGN polymorphisms and methods involving use of same 审中-公开
    L-SIGN多态性及其使用方法

    公开(公告)号：US20060292151A1

    公开(公告)日：2006-12-28

    申请号：US11093117

    申请日：2005-03-28

    申请人： Jason Gardner ,  William Olson

    发明人： Jason Gardner ,  William Olson

    IPC分类号： A61K39/395 ,  G01N33/53 ,  A61K31/715 ,  A61K31/716

    CPC分类号： G01N33/5767 ,  C07K16/109 ,  C07K16/2851 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N2500/00

    摘要： This invention concerns methods for determining whether an agent preferentially binds to at least one allelic variant of L-SIGN. The invention is also directed to agents that preferentially bind to at least one allelic variant of L-SIGN. The invention also provides methods and agents for treating and preventing disorders associated with infection by pathogens, including hepatitis C virus, that bind to particular L-SIGN allelic variants. The invention further provides methods for predicting the resistance or susceptibility of a subject to pathogen infection.

    摘要翻译： 本发明涉及用于确定试剂优先与至少一种L-SIGN等位基因变体结合的方法。 本发明还涉及优先结合至少一个L-SIGN等位基因变体的药剂。 本发明还提供用于治疗和预防与特定L-SIGN等位基因变体结合的病原体（包括丙型肝炎病毒）感染相关疾病的方法和试剂。 本发明还提供了用于预测受试者对病原体感染的抗性或易感性的方法。

    Analgesic regimen
    10.
    发明授权
    Analgesic regimen 有权

    公开(公告)号：US06605644B2

    公开(公告)日：2003-08-12

    申请号：US10002249

    申请日：2001-10-26

    申请人： Marc Kamin ,  William Olson

    发明人： Marc Kamin ,  William Olson

    IPC分类号： A61K31135

    CPC分类号： A61K31/135

    摘要： A regimen for the administration of tramadol for the treatment of analgesia is described. The regimen involves a slower initial titration rate of tramadol which results in a significantly lower percentage of discontinuations of therapy due to a lower incidence and severity of side effects.